Drugs / talnetant
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00103727 | Dec 2004 → Oct 2005 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00300963 | Dec 2004 → Oct 2005 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00101985 | Oct 2004 → Jul 2005 | irritable bowel syndrome | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00049946 | Oct 2002 → Apr 2003 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | talnetant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00101985 ↗ |
| Known as | CHEMBL10188 | ChEMBL registry synonym — accepted as the source's own label CHEMBL10188 ↗ |
| Known as | SB 223412 | ChEMBL registry synonym — accepted as the source's own label CHEMBL10188 ↗ |
| Known as | SB-223412-A | ChEMBL registry synonym — accepted as the source's own label CHEMBL10188 ↗ |
| Known as | TALNETANT HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL10188 ↗ |
| Action | Inhibit | “Neurokinin 3 receptor antagonist” CHEMBL10188 ↗ |
| Modality | Small molecule | — CHEMBL10188 ↗ |
| Target | TACR3 | “Neurokinin 3 receptor antagonist” CHEMBL10188 ↗ |